Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Dermatology

Free Subscription 02.01.2023 4 BMC Cancer 3 Cancer 5 Int J Cancer 1 Int J Dermatol 1 Intern Med 3 J Dermatol 5 J Invest Dermatol 2 Plast Reconstr Surg 2 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Cancer

1. YANG H, Xu L, Guan S, Hao X, et al
   Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial.
   BMC Cancer. 2022;22:1357.
   PubMed         Abstract available
   
   
2. QI WX, Cao L, Zheng S, Xu C, et al
   IMNI PRECISION trial protocol: a phase II, open-label, non-inferior randomized controlled trial of tailoring omission of internal mammary node irradiation for early-stage breast cancer.
   BMC Cancer. 2022;22:1356.
   PubMed         Abstract available
   
   
3. BEATTY L, Kemp E, Butow P, Girgis A, et al
   Finding My Way-Advanced: can a web-based psychosocial intervention improve the mental quality of life for women with metastatic breast cancer vs attention-control? Study protocol of a randomised controlled trial.
   BMC Cancer. 2022;22:1353.
   PubMed         Abstract available
   
   
4. MAHTANI R, Niyazov A, Arondekar B, Lewis K, et al
   Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from th
   BMC Cancer. 2022;22:1343.
   PubMed         Abstract available
   
   

   
   Cancer

5. MALLARD J, Hucteau E, Schott R, Trensz P, et al
   Early skeletal muscle deconditioning and reduced exercise capacity during (neo)adjuvant chemotherapy in patients with breast cancer.
   Cancer. 2022 Nov 17. doi: 10.1002/cncr.34533.
   PubMed         Abstract available
   
   
6. VALLANCE JK, Friedenreich CM, Wang Q, Matthews CE, et al
   Associations of device-measured physical activity and sedentary time with quality of life and fatigue in newly diagnosed breast cancer patients: Baseline results from the AMBER cohort study.
   Cancer. 2022 Nov 11. doi: 10.1002/cncr.34531.
   PubMed         Abstract available
   
   
7. RAMADAS K, Basu P, Mathew BS, Muwonge R, et al
   Effectiveness of triennial screening with clinical breast examination: 14-years follow-up outcomes of randomized clinical trial in Trivandrum, India.
   Cancer. 2023;129:272-282.
   PubMed         Abstract available
   
   

   
   Int J Cancer

8. CARIOLOU M, Abar L, Aune D, Balducci K, et al
   Postdiagnosis recreational physical activity and breast cancer prognosis: Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis.
   Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34324.
   PubMed         Abstract available
   
   
9. TSILIDIS KK, Cariolou M, Becerra-Tomas N, Balducci K, et al
   Postdiagnosis body fatness, recreational physical activity, dietary factors and breast cancer prognosis: Global Cancer Update Programme (CUP Global) summary of evidence grading.
   Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34320.
   PubMed         Abstract available
   
   
10. CHAN DSM, Vieira R, Abar L, Aune D, et al
    Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta-analysis.
    Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34322.
    PubMed         Abstract available
    
    
11. BAHAR-SHANY K, Barnabas GD, Deutsch L, Deutsch N, et al
    Proteomic Signature for Detection of High Grade Ovarian Cancer in germline BRCA mutation carriers.
    Int J Cancer. 2022 Oct 10. doi: 10.1002/ijc.34318.
    PubMed         Abstract available
    
    
12. XIA C, Yu XQ, Chen W
    Measuring population-level cure patterns for cancer patients in the United States.
    Int J Cancer. 2023;152:738-748.
    PubMed         Abstract available
    
    

    
    Int J Dermatol

13. BARTLEY BR, Moore SA, Doan HQ, Rady PL, et al
    Current treatments and emerging therapies of human polyomavirus-associated skin diseases: a comprehensive review.
    Int J Dermatol. 2022 Dec 28. doi: 10.1111/ijd.16534.
    PubMed         Abstract available
    
    

    
    Intern Med

14. SAIKI T, Harada A, Suekane H, Torisu T, et al
    Multiple Gastrointestinal Angiosarcoma Mimicking Kaposi's Sarcoma.
    Intern Med. 2022 Dec 28. doi: 10.2169/internalmedicine.1177.
    PubMed        
    
    

    
    J Dermatol

15. SAEKI H, Mabuchi T, Asahina A, Abe M, et al
    English version of Japanese guidance for use of biologics for psoriasis (the 2022 version).
    J Dermatol. 2022 Dec 29. doi: 10.1111/1346-8138.16691.
    PubMed         Abstract available
    
    
16. HAN J, Stratman S, Young JN, Poplausky D, et al
    Unique protein signatures evolve during the course of a delayed-type hypersensitivity reaction in human skin.
    J Dermatol. 2022 Dec 28. doi: 10.1111/1346-8138.16688.
    PubMed         Abstract available
    
    
17. MELIN A, Bouchereau S, Guelimi R, Bergqvist C, et al
    Safety and efficacy of high-dose clobetasol propionate 0.05% in cutaneous lichen planus.
    J Dermatol. 2022 Dec 28. doi: 10.1111/1346-8138.16689.
    PubMed         Abstract available
    
    

    
    J Invest Dermatol

18. OLSSON-BROWN A, Yip V, Ogiji ED, Jolly C, et al
    TNF-alpha mediated keratinocyte expression and release of matrix metalloproteinase 9: putative mechanism of pathogenesis in Stevens-Johnson syndrome/ toxic epidermal necrolysis.
    J Invest Dermatol. 2022 Dec 26:S0022-202X(22)02898.
    PubMed         Abstract available
    
    
19. POLUBOTHU S, Bender N, Muthiah S, Zecchin D, et al
    PTPN11 mosaicism causes a spectrum of pigmentary and vascular neurocutaneous disorders and predisposes to melanoma.
    J Invest Dermatol. 2022 Dec 22:S0022-202X(22)02891.
    PubMed         Abstract available
    
    
20. LADA G, Chinoy H, Talbot PS, Warren RB, et al
    The Relationship of Depression and Systemic Inflammation in Psoriasis; Findings from the UK Biobank.
    J Invest Dermatol. 2022 Dec 22:S0022-202X(22)02894.
    PubMed        
    
    
21. YI-PIN LEE C, Carissimo G, Teo TH, Ming Tong SJ, et al
    CD8+ T-cells trigger auricular dermatitis and blepharitis in mice post-Zika virus infection in the absence of CD4+ T-cells.
    J Invest Dermatol. 2022 Dec 22:S0022-202X(22)02893.
    PubMed         Abstract available
    
    
22. AFACH S, Le Cleach L, Sbidian E
    Placebo response in moderate-to-severe psoriasis: prevalence meta-analysis of randomised controlled trials.
    J Invest Dermatol. 2022 Dec 20:S0022-202X(22)02892.
    PubMed        
    
    

    
    Plast Reconstr Surg

23. PANAHI A, Couch KS, White PB, Chao JW, et al
    Acute Skin Failure Associated with Severe COVID-19.
    Plast Reconstr Surg. 2023;151:185e-186e.
    PubMed        
    
    
24. PETERS BR, Richards HW, Berli JU
    Optimizing Innervation in Radial Forearm Phalloplasty: Consider the Posterior Antebrachial Cutaneous Nerve.
    Plast Reconstr Surg. 2023;151:202-206.
    PubMed         Abstract available
    
    

    
    PLoS One

25. PIERA-VELAZQUEZ S, Dillon ST, Gu X, Libermann TA, et al
    Aptamer proteomics of serum exosomes from patients with Primary Raynaud's and patients with Raynaud's at risk of evolving into Systemic Sclerosis.
    PLoS One. 2022;17:e0279461.
    PubMed         Abstract available
    
    
26. CHOUPANI E, Madjd Z, Saraygord-Afshari N, Kiani J, et al
    Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells.
    PLoS One. 2022;17:e0279522.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

27. CHEN X, Sifakis EG, Robertson S, Neo SY, et al
    Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction.
    Proc Natl Acad Sci U S A. 2023;120:e2209856120.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Dermatology is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: